Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 - Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

1 Day SANN -3.04% DJIA -1.01% Russell 2K -0.91% Health Care/Life Sciences -0.28% ...

Swiss biopharmaceutical company Santhera Pharmaceuticals has named Catherine Isted as its new chief financial officer. She replaces Andrew Smith, who is stepping down after five years and will assist ...

Santhera Pharmaceuticals, a specialty pharmaceutical company focused on rare diseases, announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the ...

SANN) announces the appointment of Catherine Isted as Chief Financial Officer (CFO), effective February 24, 2025. She succeeds Andrew Smith, who, after five years at Santhera and financiall ...

Vanessa dos Reis Ferreira is head of Patient Advocacy Europe at Santhera and a rare disease specialist. Here she describes how her company is focused on understanding patient needs to develop ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance ...

Santhera Pharmaceuticals’ Agamree (vamorolone) has been accepted by the Scottish Medicines Consortium (SMC) to treat Duchenne muscular dystrophy (DMD) in patients aged four years and older. The ...

Swiss biotech Santhera has raised CHF 22 million ($23.5 million) in bridge financing that it says will allow it to fund its operations through to October, when the FDA is due to deliver a decision ...